Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study

Matsui, Motohiro, MD*; Saito, Yuya, MD*; Yamaoka, Shoko, MD*; Yokokawa, Yuichi, MD, PhD*; Morikawa, Yoshihiko, MD; Makimoto, Atsushi, MD, PhD*; Yuza, Yuki, MD, PhD*

Journal of Pediatric Hematology/Oncology: July 2018 - Volume 40 - Issue 5 - p 379–381
doi: 10.1097/MPH.0000000000001159
Original Articles

In total, 158 chemotherapy courses containing cisplatin for 37 pediatric cases of newly diagnosed cancer were divided into 2 groups depending on whether magnesium (Mg) supplementation was administered (Mg+: 92 courses) or not (Mg−: 66 courses). Renal impairment was defined as grade 2 or higher creatinine elevation (CE) after each chemotherapy course. The incidence of CE in the Mg+ was significantly lower than in the Mg− (9.8% vs. 22.7%; P=0.025). Multivariate analysis revealed that Mg supplementation significantly reduced the incidence of CE (odds ratio, 0.36; confidence interval, 0.13-0.99). In pediatric patients, Mg supplementation during cisplatin-containing chemotherapy was associated with less cisplatin-induced nephrotoxicity to prevent cisplatin-induced nephrotoxicity.

*Department of Pediatric Hematology Oncology

Clinical Research Support Center, Tokyo Metropolitan Children’s Medical Center, Musashidai, Fuchushi, Tokyo, Japan

The authors declare no conflict of interest.

Reprints: Motohiro Matsui, MD, Department of Pediatric Hematology Oncology, Tokyo Metropolitan Children’s Medical Center, 2-8-29, Musashidai, Fuchushi, Tokyo 183-8561, Japan (e-mail: motohiro612@yahoo.co.jp).

Received April 30, 2017

Accepted December 21, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.